What's surprising about the "Azacitidine and Decitabine" article is how many questions still can't be answered:
- Would decitabine have a more significant benefit if it was tested under a different protocol?
- What should change?: days per cycle, inpatient vs. outpatient, number of cycles.
- Why were the M.D. Anderson results different?
- Which lower-risk MDS patients should receive the drugs?
- If so, how soon should their treatment begin?
- How long should drug therapy continue if there is no response?
We're certainly keeping the researchers busy. In the meantime, doctors make treatment decisions based on all available information.